...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of neurology: the official journal of the European Federation of Neurological Societies >The Dystonia Discomfort Scale (DDS): A novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia
【24h】

The Dystonia Discomfort Scale (DDS): A novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia

机译：Dystonia不适（DDS）：一种监测骨髓炎毒素毒素治疗的颞叶颞型术语的新仪器

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and purpose: Conventional scales measure the effect of botulinum toxin (BT) therapy only at specific points in time. The Dystonia Discomfort Scale (DDS), a novel, easy-to-use, self-assessment scale to record temporal profiles of the effect of BT therapy in cervical dystonia (CD), is introduced and evaluated against the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). Methods: Seventy-six patients with CD (age 54.4 ± 10.9 years, 34% male) receiving ≤5 cycles of incobotulinumtoxinA (Xeomin?; Merz Pharmaceuticals, Frankfurt am Main, Germany) injections at intervals ≥10 weeks used DDS to record the severity of their symptoms daily. DDS data were compared with TWSTRS-Total scores and patients' subjective estimation (SE) of the onset (TO) and waning (TW) of the treatment effect. Results: The Toronto Western Spasmodic Torticollis Rating Scale - Total scores correlated significantly with DDS (P ≤ 0.028 at all visits evaluated). TO-DDS and TO-SE were 7.9 ± 8.6 and 7.1 ± 4.1 days, respectively; TW-DDS and TW-SE were 41.8 ± 19.2 and 45.1 ± 21.5 days, respectively. Conclusion: The Dystonia Discomfort Scale is a novel, easy-to-use, self-assessment scale for valid and sensitive monitoring of the temporal profile of the effect of BT therapy in patients with CD. DDS provides important additional information about onset, duration, waning, stability and reproducibility of the effects of BT therapy.
机译：背景和目的：常规尺度仅测量肉毒杆菌毒素（BT）治疗的特定点及时的疗效。促进肌肌肌肌瘤不适量表（DDS），新颖，易于使用，自我评估规模，用于记录宫颈Dystonia（CD）中BT治疗效果的时间谱，并评估多伦多西部痉挛性斜颈评级规模（TWSTRS）。方法：硒镉患者（54.4±10.9岁，34％男性）接受≤5次循环的Incobotulinumtoxina（Xeomin ?; Merz Pharmaceuticals，Frankfurt Am Main，德国）以间隔注射≥10周使用DDS记录严重程度他们每天症状。将DDS数据与TWSTRS-总分比和患者的主观估算（SE）进行比较，对治疗效果的发病（TO）和WANING（TW）进行了比较。结果：多伦多西方痉挛性肉饼型额定尺度 - 总分数与DDS显着相关（在所有访问中评估的P≤0.028）。 DDS和TO-SE分别为7.9±8.6和7.1±4.1天; TW-DDS和TW-SE分别为41.8±19.2和45.1±21.5天。结论：Dystonia不适等级是一种新颖，易于使用，自我评估规模，用于对CD患者的BT治疗效果的时间剖面有效和敏感的监测。 DDS提供了关于BT治疗效果的发病，持续时间，衰退，稳定性和再现性的重要信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号